September 25, 2024 10:29 AM EDT
News Briefing

Sanofi inks deal with I-Mab; Wave dis­clos­es $175M of­fer­ing on heels of DMD da­ta

ENDPOINTS

Plus, news about BioAge, Ful­crum Ther­a­peu­tics and Ar­cutis Bio­ther­a­peu­tics:

Sanofi snags Greater Chi­na rights to CD73 an­ti­body: The French phar­ma

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

2sev­en­ty bio, Bris­tol My­ers stop late-stage Abec­ma study in mul­ti­ple myelo­ma due to re­cruit­ment chal­lenges

Am­gen re­ports dual Phase 3 wins in atopic der­mati­tis and myas­the­nia gravis

Ital­ian gene ther­a­py start­up nabs $52M for rare ge­net­ic dis­ease that Mod­er­na is work­ing on

Mer­ck­'s LAG-3 plus Keytru­da com­bo fails Phase 3 in col­orec­tal can­cer

FDA OKs In­tra­Bio's drug less than a week af­ter rare dis­ease's first-ever ap­proval

sponsored

PD­Cs vs. AD­Cs: A New Fron­tier in Tar­get­ed Can­cer Ther­a­pies and the Po­ten­tial for De­vel­op­ment Part­ner­ships

A service from the Financial Times